Program
Arginine
Also written as “8% arginine + Zinc toothpaste”, “arginine/lysine” and “L Arginine”.
Its studies are mostly in Dental Caries · Dentin Sensitivity · Gastro-enteropancreatic neuroendocrine tumor · Peripheral Vascular Diseases · Peripheral Arterial Disease, led by 4 companies.
Drug pageArginine: every studyAll 124 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Colgate Palmoliveits history only | 31 open or running | phase 3since Jun 18, 2026 | Feb 4, 2015 | none ahead |
| POLYSAN Scientific & Technological Pharmaceuticalits history only | 20 open or running | phase 2since Mar 1, 2019 | Jan 16, 2017 | none ahead |
| Novartis | 10 open or running | phase 4since Aug 20, 2020 | Aug 20, 2020 | none ahead |
| Pfizerits history only | 10 open or running | no phasesince Jan 18, 2006 | Jan 18, 2006 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named arginineINNProposed as its International Nonproprietary Name in WHO's List 117
- Aug 20, 2020First study: phase 4 study in Gastro-enteropancreatic neuroendocrine tumorFirst studyNCT04524442 · 42 enrolled · Italy, Netherlands, Poland and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Novartis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04524442Gastro-enteropancreatic neuroendocrine tumor · Italy, Netherlands, Poland and more | 4 | Completed | Nov 18, 2023 | 42 |
How it is read
Names in the registry
- “8% arginine + Zinc toothpaste”, 1 entry
- “arginine/lysine”, 1 entry
- “L Arginine”, 1 entry
- “Experimental toothpaste containing fluoride and amino acid (arginine)”, 1 entry
- “arginine sodium succinate”, 1 entry
Conditions, from the studies’ own filings
- Dental Caries, 2 studies
- Dentin Sensitivity, 1 study
- Gastro-enteropancreatic neuroendocrine tumor, 1 study
- Peripheral Vascular Diseases, 1 study
- Peripheral Arterial Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.